Research Funding

Research Funding

Amandeep Bajwa, PhD:
1 K01DK091444-01A1 (Bajwa), Sphingosine-1-phosphate receptor 1 and 3 as novel targets in transplantation (3/01/2012-01/31/2017)

Michael Brown, PhD:
NIH 1R21AI118269-01A1 (PI: Mike Brown), Genetic basis of secondary lymphoid organ protection after virus infection (6/15/2015 – 5/31/2017). Total award: $429,936

Shu Man Fu, MD, PhD:
R01 AR049449 (Fu, SM), HLA-D Region in Systemic Lupus Erythematosus Pathogenesis (08/01/2005-03/31/2016)

R01 AR047988 (Fu, SM), Cellular and Genetic Basis of Systemic Lupus Erythematosus, (09/28/2001-07/31/2015)

- Shu Man Fu, MD, PhD, and Rahul Sharma, PhD:
IL2 and IL33 as therapeutic agents for lupus nephritis. (02/01/2015-01/31/2018) Total award: $577,438 (8% indirect)

Gilbert Kinsey, PhD:
K01DK088967 (Kinsey), Regulatory T cells as a novel therapeutic agent/target for acute kidney injury. (09/15/2010 – 09/14/2015)

Thu Le, MD:
National Institute of Health R01 DK 094907-01 (04/2012-03/2016)

Peter Lobo, MD:
1 R01 DK083406 (Lobo & Okusa, co-PIs), Naturally Occurring IgM Anti-Leucocyte Autoantibodies Protect Against Renal Ischemia (03/12/2010-03/11/2015)

Mark D Okusa, MD:
Coulter Translational Research Partnership (PIs: Mark Okusa and John Hossack). Image Guided, Non-Invasive, Ultrasound for Protection from Ischemia Reperfusion Injury. (7/1/15-6/3016). Total award: $100,000

1 R01 DK083406 (Lobo & Okusa, co-PIs). Naturally Occurring IgM Anti-Leucocyte Autoantibodies Protect Against Renal Ischemia (03/12/2010-03/11/2015)

- Rahul Sharma, PhD Shu Man Fu, MD, PhD:
IL2 and IL33 as therapeutic agents for lupus nephritis. (02/01/2015-01/31/2018) Total award: $577,438 (8% indirect)

- Sundararaman Swaminathan, MD:
NIH 1R01DK103043-01A1 (PI: Sundararaman Swaminathan). Targeting Cellular Iron Dynamics for Protection in Kidney Injury. (07/13/2015 – 06/30/2020) Total award: $1,777,500